Log in
NASDAQ:FBIO

Fortress Biotech Stock Forecast, Price & News

$2.20
-0.18 (-7.56 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.17
Now: $2.20
$2.39
50-Day Range
$2.32
MA: $3.65
$4.78
52-Week Range
$1.04
Now: $2.20
$4.78
Volume899,433 shs
Average Volume956,156 shs
Market Capitalization$193.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.22
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.
Read More
Fortress Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.95 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FBIO
CUSIP21976U10
Phone781-652-4500
Employees93

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.63 million
Book Value$1.02 per share

Profitability

Net Income$-39,960,000.00
Net Margins-124.63%

Miscellaneous

Market Cap$193.62 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$2.20
-0.18 (-7.56 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

How has Fortress Biotech's stock price been impacted by COVID-19 (Coronavirus)?

Fortress Biotech's stock was trading at $1.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FBIO stock has increased by 36.6% and is now trading at $2.20.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Fortress Biotech?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fortress Biotech
.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Fortress Biotech
.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.08. The biopharmaceutical company had revenue of $9.46 million for the quarter, compared to analysts' expectations of $11.59 million. Fortress Biotech had a negative net margin of 124.63% and a negative return on equity of 53.93%.
View Fortress Biotech's earnings history
.

What price target have analysts set for FBIO?

5 brokers have issued 1-year price objectives for Fortress Biotech's shares. Their forecasts range from $4.75 to $10.00. On average, they anticipate Fortress Biotech's stock price to reach $7.55 in the next twelve months. This suggests a possible upside of 243.2% from the stock's current price.
View analysts' price targets for Fortress Biotech
.

Who are some of Fortress Biotech's key competitors?

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), Opko Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 65, Pay $532.57k)
  • Mr. Michael S. Weiss, Vice Chairman & Exec. Vice Chairman of Strategic Devel. (Age 54, Pay $532.57k)
  • Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 58, Pay $1.8M)
  • Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 66, Pay $386.35k)
  • Dr. Thomas F. Schaible, Project Leader of Inflammatory Bowel Disease

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Shikiar Asset Management Inc. (0.52%), BNP Paribas Arbitrage SA (0.02%) and Diversified Trust Co (0.01%). Company insiders that own Fortress Biotech stock include George Avgerinos, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends for Fortress Biotech
.

Which major investors are buying Fortress Biotech stock?

FBIO stock was acquired by a variety of institutional investors in the last quarter, including Shikiar Asset Management Inc., Diversified Trust Co, and BNP Paribas Arbitrage SA. Company insiders that have bought Fortress Biotech stock in the last two years include Lindsay A Md Rosenwald, Malcolm Hoenlein, and Robyn Hunter.
View insider buying and selling activity for Fortress Biotech
.

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $2.20.

How big of a company is Fortress Biotech?

Fortress Biotech has a market capitalization of $193.62 million and generates $36.63 million in revenue each year. The biopharmaceutical company earns $-39,960,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Fortress Biotech employs 93 workers across the globe.

What is Fortress Biotech's official website?

The official website for Fortress Biotech is www.fortressbiotech.com.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.